{
  "trial_id": "NCT00463450",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Written informed consent",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Postmenopausal status (amenorrhea for at least 12 months)",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "45 - 65 years of age",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Application of estrogen or cyclic estrogen/progestin preparation other than the study",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "medication for at least 6 months prior to Visit 1",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Relevant impairment of well-being and mood inspite of estrogen therapy (confirmed by questionnaire scores)",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "BMI<33kg/m2",
      "label": "met",
      "evidence": "quote"
    }
  ],
  "exclusion": [
    {
      "criterion": "Uterine bleeding of unknown etiology within the last 2 years",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Previous or existing or suspected carcinoma of the breast",
      "label": "not_met",
      "evidence": "quote"
    },
    {
      "criterion": "Any malignant disease in the last 5 years",
      "label": "not_met",
      "evidence": "quote"
    },
    {
      "criterion": "Endometrial double layer thickness > 5 mm",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "History of thromboembolic events or existing thromboembolic processes",
      "label": "not_met",
      "evidence": "quote"
    },
    {
      "criterion": "Prior hormone replacement therapy with androgens within 12 months prior to Visit 1",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Major life events within the last 12 months prior to Visit 1",
      "label": "not_met",
      "evidence": "quote"
    }
  ],
  "notes": "The patient has myasthenia gravis, class IIa. She takes pyridostigmine 60 mg three times a day and still experiences symptoms that interfere with her job.",
  "_meta": {
    "topic_id": "38",
    "trial_id": "NCT00463450",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}